I-MAK Strikes Out In Final Gilead Hep C Patent Challenge
The Patent Trial and Appeal Board has rejected the last of 10 petitions to review patents covering Gilead Pharmasset LLC's blockbuster hepatitis C medications brought by the Initiative for Medicines, Access...To view the full article, register now.
Already a subscriber? Click here to view full article